Proteome-Wide Anti-Hepatitis C Virus (HCV) and Anti-HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV-Coinfected Patients
Proteome-Wide Anti-Hepatitis C Virus (HCV) and Anti-HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV-Coinfected Patients
复制标题
DOI：
10.1086/655780
复制
发表时间：
2010-09-15
影响因子：
6.4
通讯作者：
Kottilil, Shyam
中科院分区：
文献类型：
--
作者：
Burbelo, Peter D.;Kovacs, Joseph A.;Kottilil, Shyam
我们量化了在接受聚乙二醇化干扰素和利巴韦林治疗的人类免疫缺陷病毒(HIV)/HCV共感染患者中与持续病毒学反应（SVR）相关的丙型肝炎病毒（HCV）蛋白质组的抗体反应。对治疗前和治疗后样本的分析显示，SVRs患者的抗核心、抗e1和抗ns4 HCV抗体联合滴度显著降低，而复发或无反应的患者则没有。此外，抗hiv p24抗体滴度与治疗反应呈负相关。这些结果表明，分析抗HCV抗体对监测HCV治疗是有用的，特别是在区分复发患者和48周发生SVRs的患者时。
We quantified antibody responses to the hepatitis C virus (HCV) proteome that are associated with sustained virologic response (SVR) in human immunodeficiency virus (HIV)/HCV-coinfected patients treated with pegylated interferon and ribavirin. Analysis of pre- and posttreatment samples revealed significant decreases in the combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those who experienced relapse or who did not respond. Furthermore, anti-HIV p24 antibody titers inversely correlated with treatment response. These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy, especially in discriminating between those who experience relapse and those who have SVRs at 48 weeks.